Perianal fistulizing Crohn’s disease (PFCD) is associated with significant morbidity and might negatively impact the quality of life of CD patients. In the last two decades, the management of PFCD has evolved in terms of the multidisciplinary approach involving gastroenterologists and colorectal surgeons. However, the highest fistula healing rates, even combining surgical and anti-TNF agents,
Cell therapies, in which cellular material is injected, grafted, or implanted into a patient to treat a range of illnesses and medical conditions, are a vital and integral component of medicine today — promising treatment of tissue degenerative diseases, cancer, and autoimmune disorders. However, significant challenges currently exist to prevent its widespread adoption, including problems
The advancement of adoptive cell immunotherapy and the impressive clinical outcomes obtained targeting hematologic malignancies with CAR-T cells dictate for further developments towards a broader use of cellular therapeutics for more patients and more types of malignancy. The advent of iPSC technology provides new perspectives for the manufacturing of customized, tumor-targeting T/NK cells, with improved
tem cell therapies have the potential to treat many conditions, but so far there’s little proof that they do. Even so, clinics around the world offer stem cell-based treatments for a host of medical problems. New research warns that some of these treatments might not be effective and can, in fact, cause harm — sometimes
A study was conducted under the UK Regenerative Medicine Platform as part of the work of the Cell Behaviour, Differentiation and Manufacturing Hub. It comprised part of the Pluripotent Stem Cell Platform (PSCP) project funded by the Medical Research Council, the Biotechnology and Biological Sciences Research Council and the Engineering and Physical Sciences Research Council
This report includes an overview of regenerative medicine approaches to treating a variety of cancer types, along with a list of ARM member companies active in developing these therapies, global financings, an overview of the oncology-focused clinical pipeline, as well as commentary from select therapeutic developers active in this area. Key findings include: There are 416 companies worldwide active in
Reviews Gene Editing for Immune Cell Therapies Autologous T cells that have been genetically modified to express a chimeric antigen receptor targeting the B cell antigen CD19 have yielded remarkable clinical responses in patients with B cell malignancies, and are now on the market as anticancer ‘drugs’. [Nat Biotechnol] Abstract The Next Generation of CRISPR-Cas Technologies
Dr. Robert A. Preti, theCEO and President of Hitachi Chemical Advanced Therapeutics Solutions (HCATS), was recently interviewed by Global Business Reports (GBR) for their 2019 US Biopharmaceuticals report. The GBR report covers a range of topics, such as the state of the biopharma industry, new developments in biopharmaceutical manufacturing, the investment climate for cell and gene
Athersys announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the
While therapies that harness the power of the immune system against cancer have made remarkable progress against certain types of tumours, they still remain ineffective in most cancer patients. A new study has described a method of reprogramming the regulatory T cells that usually suppress immune responses into inflammatory cells that not only permit but
